Clinical trialsCompany release

Traws Pharma reports Phase 2a ratutrelvir data and plans Q4 resubmission for flu drug

🇺🇸 Traws Pharma, Inc. (TRAW) · Mon 16 Nov 2026

The US biotech says its oral COVID-19 antiviral matched PAXLOVID on symptom resolution in a 92-subject study, while tivoxavir marboxil remains under an FDA clinical hold.

Traws Pharma released its third-quarter results on 16 November 2026, alongside updates on its two lead antiviral programmes. The company reported final data from a Phase 2a study of ratutrelvir, its oral COVID-19 antiviral, and set out its plans for tivoxavir marboxil, a candidate for influenza prevention.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Traws Pharma, Inc. ↗

Article written by VigiEye from the official source (Traws Pharma, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →